| Virtual screening strategies in drug discovery C McInnes Current opinion in chemical biology 11 (5), 494-502, 2007 | 591 | 2007 |
| Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases Z Xia, C Knaak, J Ma, ZM Beharry, C McInnes, W Wang, AS Kraft, ... Journal of medicinal chemistry 52 (1), 74-86, 2008 | 222 | 2008 |
| 2-Anilino-4-(thiazol-5-yl) pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity S Wang, C Meades, G Wood, A Osnowski, S Anderson, R Yuill, M Thomas, ... Journal of medicinal chemistry 47 (7), 1662-1675, 2004 | 198 | 2004 |
| Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding S Uhrinova, D Uhrin, H Powers, K Watt, D Zheleva, P Fischer, C McInnes, ... Journal of molecular biology 350 (3), 587-598, 2005 | 187 | 2005 |
| Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop SY Wu, I McNae, G Kontopidis, SJ McClue, C McInnes, KJ Stewart, ... Structure 11 (4), 399-410, 2003 | 161 | 2003 |
| Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design G Kontopidis, SY Wu, DI Zheleva, P Taylor, C McInnes, DP Lane, ... Proceedings of the National Academy of Sciences 102 (6), 1871-1876, 2005 | 157 | 2005 |
| 4-[4-[(2-Hydroxybenzoyl) amino] phenyl] butyric acid as a novel oral delivery agent for recombinant human growth hormone A Leone-Bay, KK Ho, R Agarwal, RA Baughman, K Chaudhary, ... Journal of medicinal chemistry 39 (13), 2571-2578, 1996 | 150 | 1996 |
| Progress in the discovery of polo-like kinase inhibitors C McInnes, M Mezna, PM Fischer Current topics in medicinal chemistry 5 (2), 181-197, 2005 | 148 | 2005 |
| Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance C McInnes, A Mazumdar, M Mezna, C Meades, C Midgley, F Scaerou, ... Nature chemical biology 2 (11), 608, 2006 | 133 | 2006 |
| Discovery and characterization of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional CDK inhibitors as anticancer agents S Wang, G Griffiths, CA Midgley, AL Barnett, M Cooper, J Grabarek, ... Chemistry & biology 17 (10), 1111-1121, 2010 | 124 | 2010 |
| Progress in the evaluation of CDK inhibitors as anti-tumor agents C McInnes Drug discovery today 13 (19-20), 875-881, 2008 | 124 | 2008 |
| PLK1 as an oncology target: current status and future potential C McInnes, MD Wyatt Drug discovery today 16 (13-14), 619-625, 2011 | 121 | 2011 |
| Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors S Wang, CA Midgley, F Scaërou, JB Grabarek, G Griffiths, W Jackson, ... Journal of medicinal chemistry 53 (11), 4367-4378, 2010 | 117 | 2010 |
| Growth factor receptors: structure, mechanism, and drug discovery C McInnes, BD Sykes Peptide Science 43 (5), 339-366, 1997 | 112 | 1997 |
| Highly potent p21WAF1‐derived peptide inhibitors of CDK‐mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A DI Zheleva, C McInnes, AL Gavine, NZ Zhelev, PM Fischer, DP Lane The Journal of peptide research 60 (5), 257-270, 2002 | 90 | 2002 |
| Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics LO Kirkland, C McInnes Biochemical pharmacology 77 (10), 1561-1571, 2009 | 86 | 2009 |
| Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes MJI Andrews, C McInnes, G Kontopidis, L Innes, A Cowan, A Plater, ... Organic & biomolecular chemistry 2 (19), 2735-2741, 2004 | 85 | 2004 |
| Development of the structural basis for antimicrobial and hemolytic activities of peptides based on gramicidin S and design of novel analogs using NMR spectroscopy C McInnes, LH Kondejewski, RS Hodges, BD Sykes Journal of Biological Chemistry 275 (19), 14287-14294, 2000 | 84 | 2000 |
| Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange G Kontopidis, MJI Andrews, C McInnes, A Cowan, H Powers, L Innes, ... Structure 11 (12), 1537-1546, 2003 | 81 | 2003 |
| Strategies for the design of potent and selective kinase inhibitors C McInnes, PM Fischer Current pharmaceutical design 11 (14), 1845-1863, 2005 | 80 | 2005 |
Peter M FischerProfessor of Medicinal Chemistry, University of Nottingham在 nottingham.ac.uk 的电子邮件经过验证
